Tracking antimicrobial stewardship activities beyond days of therapy (DOT): Comparison of days of antibiotic spectrum coverage (DASC) and DOT at a single center.
Sign Up to like & getrecommendations! Published in 2023 at "Infection control and hospital epidemiology"
DOI: 10.1017/ice.2022.312
Abstract: Abstract Even though antimicrobial days of therapy did not significantly decrease during a period of robust stewardship activities at our center, we detected a significant downward trend in antimicrobial spectrum, as measured by days of… read more here.
Keywords: stewardship; days antibiotic; days therapy; dasc ... See more keywords
Implementation of an Automated Antibiotic Time-out at a Comprehensive Cancer Center
Sign Up to like & getrecommendations! Published in 2024 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae235
Abstract: Abstract Background Antimicrobial stewardship programs can optimize antimicrobial use and have been federally mandated in all hospitals. However, best stewardship practices in immunocompromised patients with cancer are not well established. Methods An antimicrobial time out,… read more here.
Keywords: cancer; time; days therapy; comprehensive cancer ... See more keywords
Effect of secure clinical messaging on chemotherapy adherence.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e18542
Abstract: e18542 Background: Oncologists offer essential clinical information to patients face-to-face or by phone. Today, patients commonly prefer digital communication. To test the effectiveness of this in patients, we deployed proprietary secure messaging (SM) to communicate… read more here.
Keywords: control; test; optimally adherent; days therapy ... See more keywords
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15030355
Abstract: Sofosbuvir (SOF) is an HCV NS5B polymerase inhibitor, and GS-331007 is its major metabolite. The aim of this study was to investigate whether clinical and pharmacological factors could influence GS-331007 intracellular (IC) concentrations in peripheral… read more here.
Keywords: factors influencing; days therapy; patients treated; influencing intracellular ... See more keywords